Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00654927 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Fampridine-SR b.i.d. (Twice Daily)

Sponsor

Acorda Therapeutics